Thomas B Ladd Selected Research

O-(glucuronic acid 2- sulfate)- (1- - 4)- O- (2,5)- anhydromannitol 6-sulfate

4/2014	Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators.
9/2013	Steroids as γ-secretase modulators.
6/2008	Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
6/2008	Substrate-targeting gamma-secretase modulators.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas B Ladd Research Topics

Disease

16	Alzheimer Disease (Alzheimer's Disease) 12/2023 - 06/2006
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 07/2015
2	Amyloid Plaque 11/2012 - 05/2012
1	Tauopathies 01/2018
1	Gliosis 07/2015
1	Parkinson Disease (Parkinson's Disease) 07/2015
1	Neuroinflammatory Diseases 07/2015
1	Malaria 08/2006

Drug/Important Bio-Agent (IBA)

9	Amyloid (Amyloid Fibrils)IBA 12/2023 - 06/2008
6	Proteins (Proteins, Gene)FDA Link 12/2023 - 08/2006
6	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2019 - 06/2008
4	Peptides (Polypeptides)IBA 01/2018 - 06/2008
4	O-(glucuronic acid 2- sulfate)- (1- - 4)- O- (2,5)- anhydromannitol 6-sulfateIBA 04/2014 - 06/2008
2	Protein Isoforms (Isoforms)IBA 04/2014 - 06/2008
2	Amyloid beta-PeptidesIBA 06/2008 - 06/2008
1	Phosphotransferases (Kinase)IBA 01/2018
1	EpitopesIBA 01/2018
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2018
1	CationsIBA 07/2015
1	SynucleinsIBA 07/2015
1	PresenilinsIBA 04/2014
1	tasiamide BIBA 12/2012
1	Presenilin-1IBA 06/2008
1	Gamma Secretase Inhibitors and ModulatorsIBA 06/2008
1	signal peptide peptidaseIBA 08/2006
1	human signal peptide peptidase like 3IBA 08/2006
1	Apolipoproteins E (ApoE)IBA 06/2006

Therapy/Procedure

4	Therapeutics 01/2018 - 06/2008